Abstract |
The efficacy and tolerance of cefodizime in lower respiratory tract infections in hospitalized adults was evaluated in an open, non-comparative multicentre trial. Cefodizime ( HR 221), was administered as a dose of 1 g by slow iv or im injection every 12 h (2 g daily) to 301 hospitalized patients aged 18-91 years. The mean duration of treatment was 10 +/- 3 days (median 9, range 1.23). All 301 patients were evaluable for tolerance, 270 were evaluable for clinical efficacy, and 204 were evaluable for bacteriological efficacy. A satisfactory clinical response was achieved in 87.8% (237/270) of patients and a satisfactory bacteriological response in 90.2% (184/204). Of the patients given the drug iv, 3.9% (6/153) had pain at the site of the injection compared with 7.4% (11/148) of those given the drug im. Tolerance was good; only five patients experienced an adverse reaction, and a relationship with cefodizime was considered probable in four of these cases. Haematological, hepatic and renal function tests revealed 27 abnormalities, all considered to have a doubtful relationship with treatment.
|
Authors | J P Sollet |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 26 Suppl C
Pg. 103-10
(Nov 1990)
ISSN: 0305-7453 [Print] England |
PMID | 2074244
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Cefotaxime
(adverse effects, analogs & derivatives, therapeutic use)
- Female
- Humans
- Injections, Intramuscular
- Injections, Intravenous
- Male
- Middle Aged
- Respiratory Tract Infections
(drug therapy, microbiology)
|